Conditions: Mesothelioma
Keywords: mesothelioma bevacizumab chemotherapy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 53
Healthy volunteers: no

Brief summary:
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab

Detailed description:
Secondary endpoints will include:

objective response rate

overall survival

In addition, the objective of the analysis of the correlative science data is to determine any association between tumor expression of VEGF/KDR complex and/or the presence of sv40 (as detected by PCR amplification) and objective response.

Arms:
arm 1: cisplatin, pemetrexed, and bevacizumab

Interventions: intervention 1: bevacizumab intervention 2: cisplatin intervention 3: pemetrexed
Intervention descriptions: intervention 1: 15 mg/kg IV every 3 weeks intervention 2: 75 mg/m2 IV every 3 weeks intervention 3: 500 mg/m2 every 3 weeks

Protocol document: